The Biocon brand is synonymous with quality. Our facilities undergo many external audits each year. US FDA, EMA, ANVISA, COFEPRIS, TGA are a few. In the Generics segment, we have served over 420 customers and distributed products across more than 60 countries. We continue to invest heavily in people, systems and technology to ensure compliance.

To our two decades of experience in developing and manufacturing complex APIs and injectable drug product formulations, we have added a high potency oral solid dosage manufacturing capability. Vertical integration is crucial in effectively managing our supply chain to address continuity of supply.

Our portfolio is robust with dossiers that have been filed in geographies around the world including US and EU. This will soon include China, Brazil and South East Asia through our international regulatory affairs department.

Our efficient and reliable supply chain unfailingly delivers our formulations across continents as per the committed schedules. This remained uninterrupted even during the 2020 pandemic and no customer faced a back-order situation due to our ability to handle such disruptions.